[On-Demand] Prescription Biosimilars - Continuing Education (CE) Credit Only Track

Tuesday, March 4, 2025, 7:00 AM - Wednesday, September 3, 2025, 11:59 PM

Discover the latest insights and strategies for managing prescription biosimilar therapies. This course will explore the key benefits and tackle the challenges of biosimilar adoption. Gain knowledge in therapeutic areas where biosimilars are transforming care. This course is intended exclusively for UC learners, with Continuing Education (CE) credits, Certificate of Completion, and/or ABIM Maintenance of Certification (MOC) points available at no cost.

Topics include:

• Biosimilar coverage across payers

• Interchangeability

• Safety and efficacy

• Value-based care

• Clinical experience

Don’t miss this opportunity to expand your knowledge and fulfill your certification requirements. Register now. This course is available at no cost to UC learners and requires a valid UC-affiliated email address for free registration.

The on-demand course* includes recorded video and resources.

*This is an on-demand activity with no specific time or location designated for participation. The learners determine whether and when to complete the activity. The content can be assessed at any point during the lifespan of the activity and there is no specific time designated for participation.

Release Date: 02/24/2025
Termination Date: 08/24/2025

This course offers Continuing Education (CE) Credits only. Participants who do not need ABIM MOC points, including non-physicians and physicians not certified by ABIM, will receive AMA PRA Category 1 Credits™ only.

If you are an ABIM board-certified physician and wish to earn ABIM MOC Points, please register for the Continuing Education (CE) Credit & ABIM MOC Track.

Registration Fees

• Free: UC Learner Only*

• $50: Non-UC Learner

* This course is intended for UC learners. During registration, you will be asked to provide your UC-affiliated email address for verification. Registrations submitted without this information or those that fail validation will be charged $50.00 registration fee on their account.

To participate in the activity and obtain Continuing Education (CE) credits, learners should

1. Register for the Course: Click on the "Register" tab or follow https://ucla.cloud-cme.com/course/courseoverview?P=5&EID=8017&IsExhibitor=false.

2. Access Activity Materials: After completing your registration, view the materials under the "Content" tab.

3. Complete the attestation and course evaluation: After engaging with the content, please complete the attestation and course evaluation form.

Your certificate will be available immediately for print or download upon completion.

1. Identify the range of FDA-approved prescription biosimilars available for treating chronic conditions.
2. Explain the regulatory approval process and clinical evidence supporting prescription biosimilars efficacy and safety.
3. Demonstrate the ability to integrate prescription biosimilars into patient treatment plans, considering individual patient needs and preferences.
4. Assess the impact of prescription biosimilar adoption on healthcare costs and patient outcomes, with a focus on the California patient population.
5. Develop strategies to address operational and clinical barriers to prescription biosimilar adoption within healthcare settings.
6. Critically evaluate the effectiveness of implemented strategies in improving prescription biosimilar utilization and reducing health disparities.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of David Geffen School of Medicine at UCLA and University of California Office of the President. The David Geffen School of Medicine at UCLA is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (1.25 hours), ABIM MOC Part 2 (1.25 hours), Non-Physician Attendance (1.25 hours)

You are not logged in.

Please click the button below to login or create a new account before continuing.

Mitigation of Relevant Financial Relationships

The Accreditation Council for Continuing Medical Education (ACCME), Standards for Integrity and Independence mandates that the accreditation manages all identified relevant financial relationship(s) before the program and adequately discloses relationships to learners. The David Geffen School of Medicine at UCLA adheres to the ACCME Standards for Integrity and Independence in accredited continuing education.

The individuals below have been identified as having a position to influence the content of this educational activity. As such, they have disclosed the absence or presence of a relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for these individuals have been mitigated.